Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
amyloid plaque
Biotech
AAIC: Roche ‘very interested’ in tau despite amyloid AD focus
Roche’s biggest bet in Alzheimer’s may be its phase 3-stage amyloid asset, but the pharma is keeping its options open when it comes to targeting tau.
James Waldron
Jul 15, 2026 8:42am
Roche nabs European approval for second Alzheimer’s test
May 12, 2026 7:07am
Protective gene sent to the liver cleared brain amyloid in mice
May 8, 2026 1:15pm
Korsana crosses into crowded Alzheimer's field with $175M
Feb 18, 2026 6:00am
Galimedix's oral Alzheimer's candidate clears ph. 1 safety test
Sep 12, 2025 11:11am
Patient death prompts Roche to adjust Alzheimer's trial
Oct 30, 2024 11:40am
